Advanced BCC

Patient Characteristics

Characteristics of patients with laBCC and mBCC enrolled in Study 16201

  laBCC (n=84)
Median age,
years (range)
70 (42-89)
Male, % 67
White, % 68
Race not reported/unknown, % 32
ECOG performance status, %
0 61
1 39
PRIOR TREATMENTS
Cancer-related surgery or radiotherapy
Patients with at least 1 prior surgery, % 83
Patients with prior radiotherapy, % 50
  mBCC (n=54)
Median age,
years (range)
63.5 (38-90)
Male, % 70
White, % 87
Race not reported/unknown, % 13
ECOG performance status, %
0 67
1 33
PRIOR TREATMENTS
Cancer-related surgery or radiotherapy
Patients with at least 1 prior surgery, % 85
Patients with prior radiotherapy, % 59

Reason for HHI discontinuation*

mBCC and laBCC patients were previously treated with HHIs (n=138)2

Disease progression/
lack of response2

79%

Intolerance to
HHI therapy2

21%
No PD-L1 or TMB testing is required before starting LIBTAYO for advanced BCC1,2
  • BCC=basal cell carcinoma; ECOG=Eastern Cooperative Oncology Group; HHI=hedgehog pathway inhibitor; laBCC=locally advanced basal cell carcinoma; mBCC=metastatic basal cell carcinoma; PD-L1=programmed death ligand 1; TMB=tumor mutational burden.